SCHEMBL2117625

SCHEMBL2117625

Cc1ccc(-c2ccc(C)c(NS(=O)(=O)c3ccc(N)cc3)c2)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 1/20 0.48
HSD17B2 P37059 1/20 0.48
ALDH1A1 P00352 3/20 0.47
LMNA P02545 1/20 0.47
HTR6 P50406 3/20 0.47
DRD2 P14416 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
DRD3 P35462 1/20 0.47
PIK3CD O00329 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CYP3A4 P08684 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PIK3CG P48736 2/20 0.46
MAPT P10636 2/20 0.44
ADRA1A P35348 1/20 0.44
PDE4A P27815 1/20 0.43
AGO2 Q9UKV8 1/20 0.43
EDNRA P25101 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119478 0.88 HSD17B2 (0.53) HSD17B1HSD17B2ALDH1A1LMNAHTR6
SCHEMBL2121431 0.88 POLB (0.54) HSD17B1HSD17B2ALDH1A1HTR6DRD2
SCHEMBL2117810 0.86 HSD17B1 (0.47) HSD17B1HSD17B2ALDH1A1LMNAHTR6
SCHEMBL2117485 0.82 TP53 (0.51) HSD17B1HSD17B2ALDH1A1LMNAHTR6
SCHEMBL2122153 0.81 GHSR (0.58) ALDH1A1MAPTHDAC3HDAC1HDAC2
SCHEMBL2118236 0.80 CYP2C9 (0.54) ALDH1A1LMNAHTR6PIK3CDSMN1; SMN2
SCHEMBL2120043 0.80 ALDH1A1 (0.47) ALDH1A1LMNAHTR6PIK3CDSMN1; SMN2
SCHEMBL2119624 0.80 SLC40A1 (0.47) HSD17B1HSD17B2ALDH1A1LMNASMN1; SMN2
SCHEMBL2118451 0.80 ALDH1A1 (0.48) ALDH1A1LMNAHTR6PIK3CDSMN1; SMN2
SCHEMBL2116804 0.79 KIT (0.46) HSD17B1HSD17B2ALDH1A1LMNAHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 HSD17B1 3178/4885HSD17B2 3651/4885ALDH1A1 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.